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Abstract 
Increased prevalence of opioid use disorder and access to medical insurance is subsequently 
increasing the likelihood that medical professionals will encounter individuals with opioid use 
disorder. Sharp increases in opioid use disorder among women mean that obstetricians, 
gynecologists, and other reproductive medicine providers may be especially likely to encounter 
such patients. Medical professionals’ understanding of treatment for opioid use disorder, and 
their roles in their patients’ treatment, may increase referrals to treatment, reduce stigma, and 
improve the quality of medical care. Treatment for opioid use disorder falls into four overlapping 
domains: medication management, medical care, behavioral/mental health care, and 
psychosocial support. In this review, we discuss these domains with an emphasis on pregnant 
women and women of reproductive age. Treatment for opioid use disorder is most effective 
when all providers coordinate care in an informed, non-judgmental, patient-centered approach.  
Keywords: opioid, methadone, buprenorphine, medication assisted treatment, substance use 
disorder 
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Introduction 
 Opioid use disorder (OUD) among pregnant women and women of reproductive age has 
been increasing since the 1990s with demographics shifting toward young, white females (1). 
The increased prevalence means that medical practitioners who typically do not encounter 
women with opioid use disorder are now more likely to encounter patients who need, or are 
receiving treatment for OUD. The aim of the present article is to review how OUD is treated, 
with an emphasis on the unique needs of pregnant women and women of reproductive age.  
In 1965, the first controlled trial demonstrating that a daily dose of methadone could 
provide a 24-hour reduction in withdrawal symptoms and craving revolutionized treatment for 
OUD (2). Methadone clinics were created, and quickly grew to become centers where patients 
could receive their daily dose of methadone, counseling, and other needed services, and 
demonstrated effectiveness in reducing illicit substance use and increasing social functioning 
(3). More recently the introduction of the opioid partial agonist/antagonist buprenorphine, and 
long-acting formulations of the opioid antagonist naltrexone have increased alternatives for 
medication assisted treatment and the settings in which treatment can take place. Regardless of 
the pharmacological intervention provided, an evidence-based biopsychosocial assessment 
helps determine placement of the patient into the most appropriate level of care. 
 The American Society of Addiction Medicine (ASAM) placement criteria (4) include five 
broad levels of care (Table 1) spread across a continuum of treatment intensity. Early 
intervention is the least intensive, involving brief interventions with minimal follow-up. Outpatient 
treatment can range from occasional office visits for counseling and medication management to 
a more intensive outpatient program involving nine or more hours per week of counseling and 
group therapy. In partial hospitalization, individuals receive services for several hours each day 
and physicians are readily available to deal with emergent medical problems, such as 
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dangerous withdrawal symptoms. In residential treatment, the individual resides at the treatment 
facility in a structured living environment and receives treatment services throughout their stay. 
Inpatient treatment is reserved for the most severe cases requiring constant medical 
supervision, such as a high likelihood of dangerous withdrawal symptoms or co-occurring 
medical or psychiatric issues that present a danger to self or others. 
Table 1. American Society of Addiction Medicine (ASAM) Levels of care and descriptions. 
ASAM Level of Care Description 
Level 0.5 Early Intervention – Brief motivational counseling or other brief 
interventions to prevent addiction from developing, further assessment 
to rule out addiction is recommended. 
Level 1.0 Outpatient Treatment – Clinical services provided for up to 5 hours per 
week. 
Level 2.0 Intensive Outpatient Treatment and Partial Hospitalization – 9 or more 
hours per week provided near-daily or daily with ready access to acute 
medical care. 
Level 3.0 Residential Treatment – Individuals reside in a facility with 24-hr staffing 
and clinical services are provided throughout the day. 
Level 4.0 Medically Managed Intensive Inpatient Services – Individuals reside in 
a facility with 24-hr staffing by medical professionals and receive clinical 
services throughout the day.  
 
 The level of care reflects the setting and intensity of treatment, but treatment across all 
levels is multifaceted, and can be described as falling into four domains: medication 
management, medical care, behavioral/mental health care, and psychosocial support (Figure 1). 
Medication management includes detoxification, maintenance on methadone or buprenorphine, 
or the use of oral or injectable naltrexone as well as management of concomitant medications. 
Medical care involves addressing medical needs that may have arisen as a result of addiction or 
have gone untreated. In the context of pregnancy, coordination and provision of prenatal care 
improves pregnancy and infant outcomes among women with OUD (5). Behavioral/mental 
health care involves treatment of co-occurring psychiatric and behavioral issues, which are 
common among individuals with OUD. Finally, psychosocial support involves addressing the 
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social determinants of health, such as poverty, housing, education, and employment. The four 
domains are not orthogonal, and integration between the domains is important to 
comprehensive care and relapse prevention; these domains are intended to serve as a 
conceptual framework for evidence-based treatment for OUD. 
Medication Management 
 All individuals with OUD will require some form of medication management as part of 
their treatment. Ceasing chronic opioid use produces extremely unpleasant withdrawal 
symptoms such as diarrhea, vomiting, sleeplessness, tachycardia, hypertension, all of which 
may be relieved by using an opioid. Depending on the severity of the problem, medication 
management options range from maintenance with full or partial opioid agonists, to medication-
assisted withdrawal (often called detoxification). 
 In the context of pregnancy complicated by OUD, maintenance with full or partial opioid 
agonists is the current consensus guidance from the ASAM (6) and the American College of 
Obstetricians and Gynecologists (7). Methadone maintenance in pregnancy significantly 
reduces the risk of preterm birth and increases fetal growth when combined with a 
comprehensive treatment program (5). Buprenorphine, a partial opioid agonist and antagonist, 
is also an option for maintenance. Like methadone, buprenorphine is taken daily at a dose 
sufficient to prevent withdrawal symptoms and drug-seeking behavior. Methadone and 
buprenorphine are equally effective in controlling opioid withdrawal and preventing illicit opioid 
use among pregnant women, although methadone facilitates greater retention in treatment (8). 
Buprenorphine, however, tends to produce less severe neonatal withdrawal symptoms and 
improved obstetrical and fetal outcomes (9). There is no clear clinical indication as to which 
medication is most appropriate for which person, thus other factors need to be considered. 
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 Methadone and buprenorphine maintenance are often conducted in substantially 
different settings. Methadone is typically dispensed from a licensed opioid treatment program, 
and patients must attend the clinic daily to receive medication and comprehensive treatment for 
an extended period of time before take-home medication is permitted per federal regulations. 
Buprenorphine can also be used in a licensed opioid treatment program, but is more typically 
prescribed by a physician in a primary care setting. The patient receives a prescription for up to 
30 days of buprenorphine and self-administers the prescribed dose. These two modes of 
delivering the maintenance medication have their benefits and limitations, especially regarding 
the other three domains of OUD treatment. With methadone maintenance, it is more likely that a 
patient will engage with counseling, psychiatric care, and psychosocial services as a result of 
daily clinic attendance. Daily clinic attendance is a barrier for some patients, due to 
employment, education, or their proximity to a methadone clinic, which are typically located in 
urban centers. For such individuals, buprenorphine and office-based opioid treatment may be 
the only possible treatment with alternate counseling arrangements. The two medications also 
differ in their insurance coverage, with Medicaid/Medicare covering methadone in most states, 
while private insurance tends to only cover buprenorphine. Both public and private insurance 
typically reimburses for the other dimensions of OUD treatment, regardless of the medication 
used for maintenance. 
Neonatal abstinence syndrome (NAS), a cluster of neurological, autonomic, and 
gastrointestinal signs, is exhibited by almost half of neonates following gestational exposure to 
opioids (10). NAS has received much attention due to its increasing prevalence and the 
relatively higher costs associated with caring for opioid-exposed infants due to longer post-
delivery hospital stays of up to several weeks and in neonatal intensive care units (11–13). NAS 
is evaluated using semi-objective observational tools, such as the Finnegan Scoring Method 
(14), and pharmacologic treatment with opioids is reserved for instances of relatively severe 
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withdrawal. The percentage of opioid-exposed neonates requiring pharmacological interventions 
for NAS varies widely between 50-90% due to differences in hospital procedures (15), 
maternal/infant bonding (16,17), maternal cigarette smoking (18), benzodiazepine use (17,19), 
and genetic factors (20). Maternal opioid dosage is not associated with increased incidence of 
NAS (21,22). It is important to keep in mind that NAS is a temporary, treatable condition and 
decisions around maternal OUD treatment should take into account many other factors, such as 
the risks associated with acquiring and using illicit drugs and overdose. Nonetheless, pregnant 
women with OUD may seek opioid-free treatment in an attempt to avoid NAS. 
While medication assisted withdrawal is not currently recommended in the setting of 
pregnancy, recent retrospective analyses of medication assisted withdrawal in pregnancy have 
suggested the risks may be more limited than previously thought (23). However, there is a 
paucity of high quality, controlled studies that support recommending withdrawal as a treatment 
in pregnancy (24). Outside of pregnancy, medication assisted withdrawal is a frequent 
medication management strategy for OUD. 
 Medication assisted withdrawal involves gradually reducing the dosage of opioids over a 
period of several days while monitoring and minimizing withdrawal symptoms. There are several 
validated measures of opioid withdrawal, such as the Clinical Opioid Withdrawal Scale and the 
Clinical Institute Narcotic Withdrawal Scale (25). Methadone is the most common opioid used 
for medication assisted withdrawal. A typical methadone withdrawal protocol involves starting at 
10-20 mg, increasing the dose up to 40 mg within the first 24 hours, followed by a gradual 
tapering of the daily dose over the following days (26). The length of the taper can be as short 
as 3 days, but short tapers are associated with higher relapse risk (27). Buprenorphine may also 
be used for medication assisted withdrawal, with a similar pattern of increasing dose in small 
(e.g., 2 mg) increments until withdrawal symptoms are managed and then tapering over the 
following days. As with methadone, successful completion of withdrawal may be associated with 
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a longer taper time (28,29). To date, methadone- and buprenorphine-facilitated tapers have 
shown near equivalence (30). 
 Non-opioids that affect withdrawal symptoms may be used in addition to, or even in 
place of opioid agonists during the withdrawal period. Alpha2-adrenergic agonists (e.g., 
clonidine, iofexidine, and guanfacine) can be used to control withdrawal symptoms while 
tapering an opioid or be used in place of opioids altogether and have shown similar 
effectiveness to methadone tapers (31). Other symptomatic medications can be used as 
needed, such as hydroxyzine for anxiety and loperamide for diarrhea. 
 Generally, medication assisted withdrawal results in minimal sustained opioid 
abstinence. For example, one study found that 80% of individuals had relapsed within 30 days 
of completing an inpatient detoxification (32). The opioid antagonist naltrexone can help to 
maintain abstinence following medication assisted withdrawal by blocking the effects of 
subsequently used opioids (33). Oral naltrexone must be taken daily and, as a result, 
compliance tends to be low (34). Long-acting injectable naltrexone avoids some of the 
compliance issues as injections are required monthly, and produces greater retention in 
treatment and abstinence from opioids than placebo (35). 
Medical Care 
Infectious diseases, including Hepatitis C Virus (HCV) and HIV, are common among 
women with OUD (36,37), due to intravenous drug use (37) and high-risk sexual behaviors (38). 
Rates of HCV among pregnant women with OUD are between 50-62% (39). Intravenous opioid 
use also carries the risk of cellulitis and abscess formation at the injection site, sepsis, 
endocarditis, osteomyelitis, and hepatitis B (7). Given the high prevalence of HCV, pregnancy is 
a critical opportunity to identify and evaluate HCV infection in high-risk populations. Frequent 
prenatal care visits offer multiple opportunities to provide patient education and counseling 
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regarding HCV transmission, disease course and treatment options to prevent further 
transmission and encourage enrollment in HCV treatment after delivery.  
Among pregnant women undergoing treatment for OUD, tobacco smoking rates are high 
(36,40,41) and concomitant use of other substances, including alcohol, marijuana, 
benzodiazepines, and cocaine is not uncommon (42). Such use, however, can lead to adverse 
maternal and infant outcomes.  For example, as in the general population, smoking among 
opioid-maintained pregnant women has been associated with lower neonatal birth weight and 
smaller birth length (43).  Prenatal exposure to opioids combined with cocaine, 
benzodiazepines, or high levels of tobacco during pregnancy is associated with more severe 
neonatal withdrawal and longer newborn hospital stays (17–19,44).  Benzodiazepines in 
addition to opioids is associated with increased risks for overdose and overdose death (45,46).   
While almost half of pregnancies in the U.S. are unintended (47), the proportion of 
unintended pregnancies in women with OUD may be greater than 85% (48). Women with OUD 
also become pregnant more often than women in the general population. In a study examining 
the reproductive health of opioid-dependent women, 54% reported having four or more 
pregnancies in their lifetime compared to 14% of a nationally representative sample of U.S. 
women (49). There are also low rates of contraceptive use among women with OUD.  Results of 
a recent systematic review suggest that only about half of women with opioid and other 
substance use disorders use any contraception (38).  Results also indicate that condoms are 
the most commonly used contraceptive method (approximately 62%), while the use of more 
effective methods (e.g., tubal ligation, implants, and IUDs) is considerably lower (approximately 
8%) (38). Integrating family planning services into substance use disorder treatment clinics 
substantially increases the use of effective contraception (50,51). 
Behavioral/Mental Health Care 
     TREATMENTS FOR OPIOID USE DISORDER     10 
 
 It is generally required that all individuals receiving treatment for OUD receive 
counseling as part of their treatment, and counseling is associated with improved treatment 
outcomes (52). Individual counseling occurring several times per week, weekly, or monthly 
enables the patient to process and become aware of triggers of relapse, keeps the treatment 
plan concordant with the patient’s needs, and allows for interventions for co-occurring social or 
family problems. Social and family relationships appear to be relatively more influential in 
substance use disorders among women, as a perceived need to maintain even unhealthy, 
abusive relationships significantly complicates recovery (53). Cognitive behavioral therapies are 
the most common counseling interventions, and trauma-informed techniques are especially 
important among pregnant women and women of reproductive age as this population has a high 
incidence of traumatization (54–56), which is associated with poorer substance use disorder 
treatment outcomes (57,58) 
 Group counseling is an effective component of treatment. In groups of peers facilitated 
by a senior peer or therapist, patients can share experiences, learn from each other’s behaviors, 
and provide support. Peer support may be especially important for pregnant women and women 
of reproductive age given the stigmatization of mothers with substance use disorders (59). 
Group settings can also be used to convey cognitive behavioral therapies, parenting training, 
and other psychosocial supports as discussed below. 
Mental/behavioral health comorbidities are present in upwards of half of individuals with 
OUD, with anxiety, depression, and antisocial personality disorders being most common (60–
62). Additionally, these disorders are differentially represented between the genders, with 
women more likely to exhibit posttraumatic stress disorder (63), anxiety disorders (64), 
depression, and borderline personality disorder (60). Thus, proper screening and treatment for 
such disorders is a necessary component of OUD treatment. If psychiatric medications are 
required, integration with the medication management component of treatment is critical.   
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Psychosocial Support 
Psychosocial support in OUD treatment is an essential component of successful recovery. 
While state of the art treatment and care are necessary, what determines adherence to care 
and relapse prevention begins with the support necessary to participate in treatment. Care 
management provides a structured process for which psychosocial support is delivered. Care 
management consists of working with the patient to enable her to access the services and care 
she may need outside of substance use treatment. Case management, is the act of working 
with the individual to identify and link specific care services and activities needed to help 
patients manage their substance abuse treatment by identifying care and services needed to 
improve their or their children’s health and well-welling. It includes a single point of contact for 
the multiple systems that the patient may need (e.g., housing, child care, legal advocacy, food, 
employment, and other programs that would assist with recovery), assisting and advocating with 
systems on the behalf of, and with the patient. Case management is community-based and 
patient centered.  Enhanced case management that combines care management to medical 
care for the mother and child and social service linkages for women with substance misuse 
disorders, are essential to recovery. Women are centered in the families and their families have 
unmet needs as well.  These stressors have a direct impact on recovery and when stressors are 
not addressed they affect relapse as well.   
Women with substance use disorders who are pregnant or have children have parenting 
deficits (65). The deficits may include ambivalent feelings about parenting, harsh punitive 
responses expressed through yelling and threatening, a lack of understanding about basic 
developmental issues and perception of infant communications as demanding and inappropriate 
(66). Parenting stress may further complicate treatment adherence. Studies have shown that 
parenting support (i.e., child care services, parenting education, parenting and family 
counseling) is needed in this population (67). An example of a parenting intervention which has 
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recently demonstrated improvements in the quality of parenting and decreases in parental 
stress is mindfulness based parenting adapted to substance misuse treatment and adapted to 
be trauma informed (55). 
Summary 
A coordinated, multidisciplinary approach is essential to provide optimal care for 
pregnant women and women of reproductive age with OUD. Components of OUD treatment 
should include medication management to stabilize illicit drug use, medical care to secure the 
patient’s physical health, behavioral/mental health care to address underlying cognitive and 
behavioral factors and co-occurring psychiatric disorders, and psychosocial support including 
parenting support and education, childcare, and transportation, reproductive health, and 
nutrition (68). A pregnant woman’s treatment plan should also include coordinated prenatal care 
co-managed by obstetrician–gynecologists and addiction medicine specialists to reduce 
obstetrical and neonatal morbidity. Obstetrical and labor and delivery providers caring for 
pregnant women with OUD should coordinate and communicate with pediatric staff responsible 
for the care of neonates with neonatal abstinence syndrome (68). Successful treatment of OUD 
among pregnant women and women of reproductive age requires the combined, coordinated 
efforts of medical and addiction professionals providing services within and across each of 
these domains to meet the specific needs of each woman.   
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Figure 1. A conceptual framework for treatment of opioid use disorder. 
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